Skip to main content
Premium Trial:

Request an Annual Quote

Protiveris Licenses Sensor Technologies from UT-Batelle

NEW YORK, Dec. 3 (GenomeWeb News) - Protiveris has licensed rights to sensor technologies from UT-Batelle, as part of its development of bioMEMS biochips for protein research, the Rockville, Md. Company said today.


The technologies, developed by scientists at Oak Ridge National Laboratory, allow users to measure biomolecular interactions with microcantilevers, the company said.   Protiveris already has biochips that use arrays of microcantilevers as biosensors.


Under the agreement, the company will be working with ORNL scientists to further develop this system, the VeriScan 3000.


"We are extremely pleased to have acquired the commercial rights to these technologies and to be working closely with Oak Ridge National Laboratory on their commercial development," Robert Menzi, Chief Operating Officer of Protiveris, said in a statement.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.